Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy-Reference-Cited by-同舟云学术

Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy

Published:2024-01 Issue: Volume:190 Page:110019
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Cortiula Francesco,Hendriks Lizza E.L.,Wijsman Robin,Houben Ruud,Steens Michelle,Debakker Sarah,Canters Richard,Trovò Marco,Sijtsema Nanna M.,Niezink Anne G.H.,Unipan Mirko,Urban Susanna,Michelotti Anna,Dursun Safiye,Bootsma Gerben,Hattu Djoya,Nuyttens Joost J.,Moretti Eugenia,Taasti Vicki T.,De Ruysscher Dirk

Funder

Bristol-Myers Squibb

European Society for Medical Oncology

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference37 articles.

1. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. Published online February 2, 2022:JCO2101308. doi:10.1200/JCO.21.01308.

2. Long-term results of NRG oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer;Bradley;J Clin Oncol,2020

4. Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer;Abravan;J Thorac Oncol,2020

5. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay;Nakamura;Radiat Res,1990

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial;Radiotherapy and Oncology;2024-11

2. Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives;Clinical and Translational Radiation Oncology;2024-11

3. A planning study of proton therapy dose escalation for non-small cell lung cancer;Physics and Imaging in Radiation Oncology;2024-07

4. Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy;Clinical Lung Cancer;2024-07

5. Dosimetric impact of bone marrow sparing for robustly optimized IMPT for locally advanced cervical cancer;Radiotherapy and Oncology;2024-06